Effect of Human Urinary Kallidinogenase on Inflammatory Factors in Acute Ischemic Stroke (KIF-AIS)

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Human urinary kininogenase(HUK)

Experimental group (HUK plus routine clinical treatment): administered within 48 hours of AIS onset, 0.15PNA unit was dissolved in 100ml sodium chloride injection by intravenous infusion for not less than 50 minutes, once a day.

OTHER

Placebo

Placebo group (Normal sodium chloride injection plus routine clinical treatment): Normal sodium chloride administered within 48 hours of AIS onset, by intravenous infusion for not less than 50 minutes, once a day.

Trial Locations (1)

150001

RECRUITING

Zhongling Zhang, Harbin

All Listed Sponsors
lead

First Affiliated Hospital of Harbin Medical University

OTHER